SuperworthMaravai Lifesciences EV/EBIT MRVI
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2022.
- Today, Oct 23, 2026
- n/m
- an operating loss
- Last meaningful
- 17.6×
- Feb 2026
- 5-year median
- 10.6×
- 5-year range
- 5.8× to 27.3×
- Peer median
- 10.0×
Maravai Lifesciences has no meaningful EV/EBIT today: it made an operating loss of $117.1M over the last twelve months.
It was last meaningful in Feb 2026, at 17.6×.
On the days it had one over the last 5 years, its median was 10.6×, from 5.8× in Jan 2023 to 27.3× in Feb 2024.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 17.6× | 17.0× | 21.3× |
| 2025 | 18.4× | 7.1× | 20.5× |
| 2024 | 27.3× | 18.4× | 27.3× |
| 2023 | 22.1× | 5.8× | 22.3× |
| 2022 | 6.3× | 5.9× | 19.1× |
Against its peers
Companies in Drug Manufacturers - General nearest Maravai Lifesciences' size, closest first, today.
| Company | EV/EBIT |
|---|---|
| MRVIMaravai Lifesciences | n/m |
| HRMYHarmony Biosciences | 6.9× |
| ANIPANI Pharmaceuticals | 10.5× |
| PBHPrestige Consumer Healthcare | 14.5× |
| PAHCPhibro Animal Health | 11.7× |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 7.6× |
| NRIXNurix Therapeutics | 7.1× |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 12.2× |
| OGNOrganon | 9.5× |
| Peer median | 10.0× |
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Maravai Lifesciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.